←
Dolapo14,354 posts
Dolapo avatar

Dolapo

@_ottun

MD| IM resident| @accintouch IM program| Aspiring 🫀

◷ Joined August 2011▧ 11 Photos and videos
Saad Ur Rahman avatar
⟳ Dolapo retweeted
Saad Ur Rahman@SaadUrRahman55·Nov 9

7. OPTIMAL-DIABETES: In patients with type 2 diabetes and high cardiovascular risk, a systolic blood-pressure target below 120 mm Hg did not result in fewer major cardiovascular events than a target below 140 mm Hg.

Saad Ur Rahman avatar
⟳ Dolapo retweeted
Saad Ur Rahman@SaadUrRahman55·Nov 9

5. OPTIMAL-Stroke: Targeting a systolic BP of less than 120 mm Hg lowered the incidence of major cardiovascular events compared with targeting a systolic BP of less than 140 mm Hg in patients with previous ischemic stroke or transient ischemic attack.

Saad Ur Rahman avatar
⟳ Dolapo retweeted
Saad Ur Rahman@SaadUrRahman55·Nov 9

4. REDUCE: Spironolactone-based blood pressure management significantly reduced home SBP compared with standard care at 3 months, with the reduction sustained at 6 months.

AHA Science avatar
⟳ Dolapo retweeted
AHA Science@AHAScience·Nov 9

SYNCHRONIZE-CVOT results presented at #ScientificSessions26 In adults with obesity and established cardiovascular or chronic kidney disease, or increased cardiovascular risk, survodutide was non-inferior to placebo for a composite of cardiovascular death, non-fatal cardiovascular events, coronary revascularization, and heart failure events, while also improving cardiometabolic markers.

Post attachment
AHA Science avatar
⟳ Dolapo retweeted
AHA Science@AHAScience·Nov 9

ATTAIN-OSA results presented at #ScientificSessions26 Among adults with moderate-to-severe OSA and overweight or obesity without diabetes, orforglipron significantly reduced apnea-hypopnea index compared with placebo at 52 weeks, both in participants using and not using positive airway pressure therapy.

Post attachment
NEJM avatar
⟳ Dolapo retweeted
NEJM@NEJM·Nov 7

Presented at #ScientificSessions26: In patients with type 2 diabetes and high cardiovascular risk, a systolic blood-pressure target below 120 mm Hg did not result in fewer major cardiovascular events than a target below 140 mm Hg. Full OPTIMAL-DIABETES trial results: nej.md/3UZYKCy @AHAScience

Post attachment
NEJM avatar
⟳ Dolapo retweeted
NEJM@NEJM·Nov 7

Presented at #ScientificSessions26: In patients with previous ischemic stroke or transient ischemic attack, a systolic blood-pressure target below 120 mm Hg was associated with fewer major cardiovascular events than a target below 140 mm Hg. Full OPTIMAL-STROKE trial results: nej.md/3UasT1O @AHAScience

Post attachment
AHA Science avatar
⟳ Dolapo retweeted
AHA Science@AHAScience·Nov 7

OPTIMAL-STROKE results presented at #ScientificSessions26 Targeting a systolic BP of less than 120 mm Hg lowered the incidence of major cardiovascular events compared with targeting a systolic BP of less than 140 mm Hg in patients with previous ischemic stroke or transient ischemic attack.

Post attachment
AHA Science avatar
⟳ Dolapo retweeted
AHA Science@AHAScience·Nov 7

REDUCE results presented at #ScientificSessions26 Spironolactone-based blood pressure management significantly reduced home SBP compared with standard care at 3 months, with the reduction sustained at 6 months.

Post attachment
AHA Science avatar
⟳ Dolapo retweeted
AHA Science@AHAScience·Nov 7

OCEANIC-STROKE results presented at #ScientificSessions26 In patients with recent non-cardioembolic ischemic stroke (NCIS) or high-risk TIA, asundexian reduced ischemic stroke with similar bleeding versus placebo across all FRS risk categories.

Post attachment
JAMA avatar
⟳ Dolapo retweeted
JAMA@JAMA_current·Nov 7

Presented at #ScientificSessions26: Among veterans with stable #CoronaryArteryDisease in extended follow-up of the COURAGE randomized trial, an initial strategy of #PercutaneousCoronaryIntervention plus optimal medical therapy did not reduce long-term risk of death or myocardial infarction vs optimal medical therapy alone. These findings do not support a routine strategy of elective upfront percutaneous coronary intervention to reduce long-term ischemic outcomes in this population. ja.ma/483lh4o @AHAMeetings @AHAScience

Post attachment
NEJM avatar
⟳ Dolapo retweeted
NEJM@NEJM·Nov 7

Presented at #ScientificSessions26: Among patients with cardiovascular disease and high lipoprotein(a) levels, pelacarsen lowered the lipoprotein(a) level, but the risk of major cardiovascular events was similar with pelacarsen and placebo. Full phase 3 Lp(a)HORIZON trial results: nej.md/4AcZL9n @AHAScience

Post attachment
AHA Science avatar
⟳ Dolapo retweeted
AHA Science@AHAScience·Nov 7

🧵/ Late breaking science results from #ScientificSessions26 will be posted to this thread at the time of presentation: ZEUS Lp(a) HORIZON OCEANIC-STROKE REDUCE OPTIMAL-Stroke STREAM Yoga-CaRe HF Trial SUPERIOR RACE-CARS ATTAIN-OSA SYNCHRONIZE-CVOT ⬇️ (bookmark this post)

AHA Science avatar
⟳ Dolapo retweeted
AHA Science@AHAScience·Nov 7

ZEUS results presented at #ScientificSessions26. Lowering interleukin-6 levels with ziltivekimab did not lower the risk of cardiovascular events in patients with ASCVD, CKD, and cardiovascular inflammation compared to placebo.

Post attachment
AHA Science avatar
⟳ Dolapo retweeted
AHA Science@AHAScience·Nov 7

Lp(a) HORIZON results presented at #ScientificSessions26 Pelacarsen substantially lowered lipoprotein(a) but did not reduce risk of MACE compared to placebo in patients on guideline-directed medical therapy for secondary prevention of CVD.

Post attachment